American journal of therapeutics · 2025
Scropifav Antivenom Versus Supportive Care Alone in the Treatment of Pediatric Scorpion Envenomation.
СтатьяСравнительное исследованиеНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Kestenbom Inbal, Bar-Moshe Shaked, Test Gidon, Kaplan Or, Grupel Tal, Shilo Michael, Bilenko Natalya, Friger Michael, Maimon Michal S, Scolnik Dennis, Glatstein Miguel
Аннотация
BACKGROUND: Scorpion envenomation is a significant public health concern in specific regions and can have severe consequences in pediatric patients. The efficacy of antivenom treatment remains controversial.
OBJECTIVE: To compare the clinical course and outcomes of pediatric scorpion envenomation in patients receiving SCORPIFAV antivenom versus supportive care alone.
METHODS: We conducted a retrospective study of children aged 0-18 years presenting with grade ≥2 scorpion envenomation to the pediatric emergency department at Soroka University Medical Center, Israel, between 2014 and 2020. Clinical outcomes were compared between patients who received SCORPIFAV and those treated with supportive care alone.
RESULTS: A total of 194 children were included (median age: 3 years, interquartile range: 2-8 years); 125 received SCORPIFAV and 69 received supportive care only. Patients treated with SCORPIFAV required less sedation (10.3% vs. 23.4%, P = 0.02), less analgesia (53.3% vs. 81.3%, P < 0.001), and fewer antihypertensive medications (0% vs. 17.2%, P < 0.001). SCORPIFAV administration was associated with higher odds of requiring minimal additional treatment (OR = 2.568, 95% CI, 1.168-5.646, P = 0.019). No significant differences were found in pediatric intensive care unit admission rates or length of stay.
CONCLUSIONS: In pediatric patients with grade ≥2 scorpion envenomation, SCORPIFAV use was associated with reduced need for sedatives, analgesics, and antihypertensive medications. These findings suggest that early administration of SCORPIFAV in the emergency setting may help attenuate the sympathetic response and reduce overall treatment intensity.
OBJECTIVE: To compare the clinical course and outcomes of pediatric scorpion envenomation in patients receiving SCORPIFAV antivenom versus supportive care alone.
METHODS: We conducted a retrospective study of children aged 0-18 years presenting with grade ≥2 scorpion envenomation to the pediatric emergency department at Soroka University Medical Center, Israel, between 2014 and 2020. Clinical outcomes were compared between patients who received SCORPIFAV and those treated with supportive care alone.
RESULTS: A total of 194 children were included (median age: 3 years, interquartile range: 2-8 years); 125 received SCORPIFAV and 69 received supportive care only. Patients treated with SCORPIFAV required less sedation (10.3% vs. 23.4%, P = 0.02), less analgesia (53.3% vs. 81.3%, P < 0.001), and fewer antihypertensive medications (0% vs. 17.2%, P < 0.001). SCORPIFAV administration was associated with higher odds of requiring minimal additional treatment (OR = 2.568, 95% CI, 1.168-5.646, P = 0.019). No significant differences were found in pediatric intensive care unit admission rates or length of stay.
CONCLUSIONS: In pediatric patients with grade ≥2 scorpion envenomation, SCORPIFAV use was associated with reduced need for sedatives, analgesics, and antihypertensive medications. These findings suggest that early administration of SCORPIFAV in the emergency setting may help attenuate the sympathetic response and reduce overall treatment intensity.